Collaboration - December 28, 2020
Ilya Pharma extends research collaboration with Uppsala University
Ilya Pharma has signed a 2-year extension to its immunophysiology and synthetic biology research agreement with Uppsala University, Department of Medical Cell Biology. The new knowledge to be generated will help further de-risk and accelerate development of Ilya’s pipeline of advanced therapies based on modified lactic acid bacteria expressing human chemokines beyond acute skin wounds […]
Clinical Trials - October 13, 2020
Ilya Pharma completes patient recruitment in first-in-human Phase I trial
Ilya Pharma has completed recruitment for a Phase I trial of its lead candidate ILP100-Topical. Progress has been rapid considering ILP100 is the first drug based on genetically engineered Lactobacillus to be approved to enter trials which has necessitated innovations in CMC, bioassays and protocol development, states the company. Upon successful completion, the company plans […]
Intellectual Property - September 2, 2020
Ilya Pharma awarded US Utility Patent
Ilya Pharma has announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,696,974 to the company. The patent includes broad claims that cover a plasmid capable of expressing the protein CXCL12 in lactic acid bacteria, transformed lactic acid bacterial strains comprising the plasmid, and a number of products comprising […]
Biotech Business - June 4, 2020
Ilya Pharma selected for Springboard’s Health Innovation Hub
Ilya Pharma is one of ten life science companies selected this year for Springboard Enterprises’ Health Innovation Hub: Life Science. The company joins over 800 experienced “been there, run that” entrepreneurs who make up the Springboard Alumnae Network, it states in its press release. This year’s cohort will convene virtually over the next several months […]
